What is NCT04512345 Investigating?
NCT04512345 is a clinical trial investigating the use of aminolevulinic acid hydrochloride in patients with moderate to severe hidradenitis suppurativa [1]. The trial aims to evaluate the efficacy and safety of this treatment for the condition [1].
How is Aminolevulinic Acid Hydrochloride Used?
Aminolevulinic acid hydrochloride is a photosensitizing agent. When applied to the skin and exposed to specific wavelengths of light, it is converted into protoporphyrin IX, which then generates reactive oxygen species. These reactive oxygen species can target and destroy abnormal cells, including those involved in inflammatory processes seen in hidradenitis suppurativa [1].
What are the Goals of the Clinical Trial?
The primary objective of NCT04512345 is to assess the clinical response of patients with moderate to severe hidradenitis suppurativa treated with aminolevulinic acid hydrochloride [1]. Secondary objectives include evaluating the safety and tolerability of the treatment and measuring changes in disease activity [1].
What is Hidradenitis Suppurativa?
Hidradenitis suppurativa is a chronic, inflammatory skin condition characterized by painful lumps, abscesses, and scarring, typically affecting areas with apocrine sweat glands like the armpits, groin, and under the breasts [1]. It can significantly impact a patient's quality of life [1].
What Other Trials Involve Aminolevulinic Acid Hydrochloride?
DrugPatentWatch.com tracks clinical trials and patent information for various drugs. While NCT04512345 is specifically focused on hidradenitis suppurativa, aminolevulinic acid hydrochloride has been studied for other dermatological conditions, including actinic keratosis and certain skin cancers [1].
What Are the Potential Risks of Aminolevulinic Acid Hydrochloride Treatment?
As with many medical treatments, there are potential risks associated with aminolevulinic acid hydrochloride. These can include localized skin reactions such as redness, burning, itching, and increased sensitivity to light (photosensitivity) at the application site [1].
Cited Sources
1. ClinicalTrials.gov